• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Oct. 29, 2014

View Archived Issues

Receptos shows Midas 'TOUCHSTONE' in phase II UC trial; stock surges

Can outcomes get any better for Receptos Inc.? That's certainly one question investors, analysts and even company officials were thinking after Receptos disclosed top-line phase II data on lead compound RPC1063 in ulcerative colitis (UC) after Monday's market close. Read More

What's not too 'alike'? Analysts cheer Amgen earnings, biosimilars

Amgen Inc.'s moves into the biosimilar space drew attention during the company's business review meeting, which followed the release of investor-pleasing third quarter financial results that showed the company beating estimates and included higher guidance for the full year's earnings. Read More

Advent to invest in early, midstage firms with $225M fund

LONDON – Advent Venture said it will stick to its strategy of making large investments in early and midstage biotechs with its second dedicated life sciences fund, which just closed at £145.5 million (US$235 million). Read More

BMS in $475M option deal to acquire F-Star Alpha, HER2 drug FS102

DUBLIN – Bristol-Myers Squibb Co. is paying $50 million up front and could pay another $425 million to acquire F-Star Alpha Ltd. and its human epidermal growth factor receptor 2 (HER2)-targeted therapy, FS102. Read More

China's Betta buys into Xcovery's ALK inhibitor with $20M investment

SHANGHAI – Biotech acquisitions are increasingly becoming a part of the Chinese outbound investment story. This time around, up and comer Zhejiang Betta Pharmacuetical Co. has made a commitment to invest $20 million in equity in Xcovery Inc., of West Palm Beach, Fla. Read More

Medicines Co. fends off Mylan's Angiomax ANDA

A U.S. court cleared a major generic threat to The Medicines Co.'s top-seller, Angiomax (bivalirudin), ruling Monday that Mylan Inc.'s abbreviated new drug application (ANDA) infringed on a patent protecting the anticoagulant through 2028. Read More

Transplanted stem cells release dopamine in PD model, study shows

HONG KONG – Chinese researchers have demonstrated that grafted neural stem cells directly release dopamine into the damaged striata of rat brains in vivo and partially rescued a model of Parkinson's disease (PD), providing proof of concept for the feasibility of that technique for treating PD in humans. Read More

China's cross-border partnering deals set to break record in 2014

SUZHOU, China – The China growth story continues to buoy the life science industry, even in the face of challenging headwinds of change. That was the message from PwC experts who extensively surveyed executives and innovators across device, service, venture capital and pharma, many of whom were in the room for the recent collegial ChinaBio Leadership Retreat in Changshu. Read More

Financings

Imevax GmbH, of Munich, Germany, completed a €7.5 million (US$9.6 million) series A financing round. Read More

Stock movers

Read More

Other news to note

Araim Pharmaceuticals Inc., of Tarrytown, N.Y., said it was awarded FDA fast track designation for lead compound ARA290 for treating sarcoidosis-associated small fiber neuropathy (SFN). Read More

In the clinic

Alnylam Pharmaceuticals Inc., of Cambridge, Mass., and The Medicines Co. (MDCO), of Parsippany, N.J., filed a clinical trial application with the U.K. Medicines and Healthcare Products Regulatory Agency to initiate a phase I trial with ALN-PCSsc to treat hypercholesterolemia. The subcutaneously administered RNAi therapeutic uses Alnylam's enhanced stabilization chemistry (ESC)-GalNAc-siRNA conjugate delivery platform and targets the gene proprotein convertase subtilisin/kexin type 9, or PCSK9, which affects the metabolism of low-density lipoprotein cholesterol (LDL-C). Read More

Pharma: Other news to note

CSL Behring, of King of Prussia, Pa., said its Swiss affiliate and Enable Injections LLC, of Franklin, Ohio, signed a long-term development agreement for a drug delivery system. Read More

Regulatory front

Hikma Pharmaceuticals plc, of London, reported that it received a warning letter last week from the FDA stemming from an inspection of its manufacturing facility in Portugal earlier this year. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 4, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • KT-621: a first-in-class STAT6 degrader for Th2-driven diseases

    BioWorld Science
    STAT6 plays a central role in regulating Th2-driven immune responses. Recent studies have identified gain-of-function mutations in the STAT6 gene that are...
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe